CatalystMarker
← board

SION

Sionna Therapeutics Inc.distress 3/10 · well-funded / low risk
$44.37-1%today-10% from 52w high
sionnatx.com59 employeesFounded 2019Waltham, MABiotechnology
Respiratory 2
Lead: cystic fibrosis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$63M
Runway
0.9 yrs
Shares 1y
+2%

Price & events

+6.2% over 6M
$33.51$41.46$49.41Jan 26Apr 26Jul 261.1Mdilution: S-3ASR shelf_registration (2026-03-02)catalyst: PHASE2 SION-719 (2026-07-01) — click to opencatalyst: PHASE1 SION-451 (2026-06-30) — click to opencatalyst: PHASE2 SION-719 (2026-06-30) — click to opencatalyst: PHASE1 SION-451, SION-2222, SION-109 (2026-06-01) — click to openrating: Citizens: Market Outperform (2026-05-26)rating: Freedom Broker: Buy → Hold (2026-05-20)rating: Stifel: Buy (2026-05-18)rating: BTIG: Buy (2026-05-13)rating: Wedbush: Outperform (2026-05-05)rating: Jones Trading: Buy (2026-04-28)rating: BTIG: Buy (2026-04-27)rating: Guggenheim: Buy (2026-03-03)
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-2.0%
1W
+11.3%
1M
+15.7%
3M
+4.7%
6M
+124.4%
1Y
2Y
5Y
+77.5%
All

Overview

Market Cap
$2.00B
Volume
58.77K
52 Week Range
$16.74 – $49.41
Total Shares
45.15M
Float Shares
16.76M
Short %
19.86%
% Held by Insiders
6.85%
% Held by Institutions
100.03%
RVOL
0.11x

Pipeline stages · 1 programs

SION-719
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved

Pipeline · 2 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-07
Phase 2SION-719Cystic Fibrosis (CF)16active not recruiting
2026-06
Phase 1SION-451, SION-2222, SION-109Cystic Fibrosis (CF)144recruiting

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 45,150,330 · 0 offerings/1y · 0 PIPEs
  • 2026-03-02S-3ASRshelf_registration
  • 2025-02-07424B4offering
  • 2025-02-06EFFECTshelf_effective
  • 2025-02-03S-1/Ashelf_registration
  • 2025-01-17S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $52 (+16% upside) · 10 analysts
  • 2026-05-26CitizensMarket Outperform
  • 2026-05-20Freedom BrokerBuy → Hold
  • 2026-05-18StifelBuy
  • 2026-05-13BTIGBuy
  • 2026-05-05WedbushOutperform
  • 2026-04-28Jones TradingBuy

Competitors — cystic fibrosis

  • MRKMerck & Co., Inc.$318.8B · D3
  • VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
  • SNYSanofi$52.5B · D1
  • INSMINSMED Inc$22.9B · D2
  • KRYSKrystal Biotech, Inc.$9.7B · D1
  • FDMT4D Molecular Therapeutics, Inc.$524M · D5
  • ARCTArcturus Therapeutics Holdings Inc.$166M · D2
  • PHGEBiomX Inc.$2M · D8

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.